{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:25:31Z","timestamp":1791919531971,"version":"4.3.4"},"reference-count":121,"publisher":"Impact Journals, LLC","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2020,8,3]]},"DOI":"10.18632\/aging.103794","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T12:08:03Z","timestamp":1596456483000},"page":"15856-15874","source":"Crossref","is-referenced-by-count":108,"title":["Pompe disease: pathogenesis, molecular genetics and diagnosis"],"prefix":"10.18632","volume":"12","author":[{"given":"Simona","family":"Taverna","sequence":"first","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cammarata","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Colomba","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafina","family":"Sciarrino","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Zizzo","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Francofonte","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zora","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Scalia","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Brando","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia Lo","family":"Curto","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela Maria","family":"Marsana","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Olivieri","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vitale","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Duro","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB-CNR), National Research Council of Italy, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction.","volume":"19","author":"van der Spoel","year":"2012","journal-title":"J Cell Biol"},{"key":"2","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.bbamcr.2008.12.001","article-title":"Lysosomal disorders: from storage to cellular damage.","volume":"179","author":"Gieselmann","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cell.2020.01.017","article-title":"SnapShot: lysosomal storage diseases.","volume":"18","author":"Puertollano","year":"2020","journal-title":"Cell"},{"key":"4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/tra.12714","article-title":"Lysosomal size matters.","volume":"2","author":"Huber","year":"2020","journal-title":"Traffic"},{"key":"5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal storage diseases: from pathophysiology to therapy.","volume":"6","author":"Ballabio","year":"2015","journal-title":"Annu Rev Med"},{"key":"6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.21037\/atm.2018.11.39","article-title":"Lysosomal storage disease overview.","volume":"6","author":"Sun","year":"2018","journal-title":"Ann Transl Med"},{"key":"7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.21037\/atm.2019.05.29","article-title":"Pompe disease: what are we missing?","volume":"7","author":"Schoser","year":"2019","journal-title":"Ann Transl Med"},{"key":"8","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/humu.23878","article-title":"GAA variants and phenotypes among 1,079 patients with pompe disease: data from the pompe registry.","volume":"4","author":"Toscano","year":"2019","journal-title":"Hum Mutat"},{"key":"9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","article-title":"Pompe disease: literature review and case series.","volume":"3","author":"Dimachkie","year":"2014","journal-title":"Neurol Clin"},{"key":"10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again.","volume":"6","author":"Raben","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline.","volume":"8","author":"Martins","year":"2006","journal-title":"Genet Med"},{"key":"12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1042\/bj2890681","article-title":"Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites.","volume":"28","author":"Reuser","year":"1993","journal-title":"Biochem J"},{"key":"13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0167-4781(87)90064-9","article-title":"Cell-free translation of human lysosomal alpha-glucosidase: evidence for reduced precursor synthesis in an adult patient with glycogenosis type II.","volume":"91","author":"Reuser","year":"1987","journal-title":"Biochim Biophys Acta"},{"key":"14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI112262","article-title":"Trafficking of lysosomal enzymes in normal and disease states.","volume":"7","author":"Kornfeld","year":"1986","journal-title":"J Clin Invest"},{"key":"15","first-page":"2223","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation.","volume":"26","author":"Reuser","year":"1993","journal-title":"J Biol Chem"},{"key":"16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ymgme.2007.07.006","article-title":"Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a canadian cohort of individuals with glycogen storage disease, type II.","volume":"9","author":"Geraghty","year":"2007","journal-title":"Mol Genet Metab"},{"key":"17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy.","volume":"1","author":"Raben","year":"2018","journal-title":"Neurotherapeutics"},{"key":"18","volume-title":"StatPearls","author":"Mohiuddin","year":"2019"},{"key":"19","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.celrep.2019.09.073","article-title":"Glycogen dynamics drives lipid droplet biogenesis during brown adipocyte differentiation.","volume":"2","author":"Dubois-Chevalier","year":"2019","journal-title":"Cell Rep"},{"key":"20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11910-012-0333-0","article-title":"Neuromuscular disorders of glycogen metabolism.","volume":"1","author":"Bruno","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ymgme.2017.07.012","article-title":"The role of epigenetics in lysosomal storage disorders: uncharted territory.","volume":"12","author":"Tayebi","year":"2017","journal-title":"Mol Genet Metab"},{"key":"22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41436-018-0103-8","article-title":"microRNAs as biomarkers in pompe disease.","volume":"2","author":"Della Casa","year":"2019","journal-title":"Genet Med"},{"key":"23","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/acn3.50800","article-title":"Identification of serum microRNAs as potential biomarkers in pompe disease.","volume":"6","author":"Gallardo","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.bbcan.2014.10.001","article-title":"Liquid biopsies in lung cancer: the new ambrosia of researchers.","volume":"184","author":"Santini","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ajmg.a.35662","article-title":"How to describe the clinical spectrum in pompe disease?","volume":"16","author":"Reuser","year":"2013","journal-title":"Am J Med Genet A"},{"key":"26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset pompe disease (LOPD): an update on clinical aspects.","volume":"7","author":"Musumeci","year":"2019","journal-title":"Ann Transl Med"},{"key":"27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ymgme.2013.08.005","article-title":"Late-onset pompe disease is prevalent in unclassified limb-girdle muscular dystrophies.","volume":"11","author":"Vissing","year":"2013","journal-title":"Mol Genet Metab"},{"key":"28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13023-016-0442-y","article-title":"Childhood pompe disease: clinical spectrum and genotype in 31 patients.","volume":"1","author":"Michelakakis","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"29","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile pompe\u2019s disease: 20 original cases compared with 133 cases from the literature.","volume":"11","author":"van der Ploeg","year":"2003","journal-title":"Pediatrics"},{"key":"30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jpeds.2019.08.058","article-title":"Clinical and molecular disease spectrum and outcomes in patients with infantile-onset pompe disease.","volume":"21","author":"Kishnani","year":"2020","journal-title":"J Pediatr"},{"key":"31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13023-020-01353-4","article-title":"Late-onset pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.","volume":"1","author":"Buyse","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset pompe disease: a systematic literature review.","volume":"12","author":"Kishnani","year":"2017","journal-title":"Mol Genet Metab"},{"key":"33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/ene.13835","article-title":"Central nervous system involvement in late-onset pompe disease: clues from neuroimaging and neuropsychological analysis.","volume":"2","author":"Toscano","year":"2019","journal-title":"Eur J Neurol"},{"key":"34","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2174\/1566524014666141010131649","article-title":"Late-onset glycogen storage disease type 2.","volume":"1","author":"Padovani","year":"2014","journal-title":"Curr Mol Med"},{"key":"35","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in the Netherlands: implications for diagnosis and genetic counselling.","volume":"7","author":"van der Ploeg","year":"1999","journal-title":"Eur J Hum Genet"},{"key":"36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jnnp-2014-310164","article-title":"LOPED study: looking for an early diagnosis in a late-onset pompe disease high-risk population.","volume":"8","author":"Massa","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"37","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1542\/peds.2007-2222","article-title":"Early detection of pompe disease by newborn screening is feasible: results from the taiwan screening program.","volume":"12","author":"Hwu","year":"2008","journal-title":"Pediatrics"},{"key":"38","doi-asserted-by":"publisher","first-page":"e000182","DOI":"10.1136\/bmjpo-2017-000182","article-title":"Incidence of infantile pompe disease in the maroon population of french guiana.","volume":"2","author":"Benoist","year":"2018","journal-title":"BMJ Paediatr Open"},{"key":"39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/BF02185782","article-title":"Localization and ordering of acid alpha-glucosidase (GAA) and thymidine kinase (TK1) by fluorescence in situ hybridization.","volume":"9","author":"Hirschhorn","year":"1996","journal-title":"Hum Genet"},{"key":"40","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1002\/mus.880181415","article-title":"Genetic defects in patients with glycogenosis type II (acid Maltase deficiency).","volume":"3","author":"Plotz","year":"1995","journal-title":"Muscle Nerve Suppl"},{"key":"41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1089\/dna.1991.10.283","article-title":"Isolation and partial characterization of the structural gene for human acid alpha glucosidase.","volume":"1","author":"Hirschhorn","year":"1991","journal-title":"DNA Cell Biol"},{"key":"42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1750-1172-7-35","article-title":"A cross-sectional single-centre study on the spectrum of pompe disease, german patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.","volume":"7","author":"Mengel","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"43","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00415-008-0714-0","article-title":"Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II.","volume":"25","author":"Tsai","year":"2008","journal-title":"J Neurol"},{"key":"44","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1002\/jcb.27624","article-title":"A computational method to characterize the missense mutations in the catalytic domain of GAA protein causing pompe disease.","volume":"12","author":"Zayed","year":"2019","journal-title":"J Cell Biochem"},{"key":"45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/s0960-8966(01)00247-4","article-title":"Identification of six novel mutations in the acid alpha-glucosidase gene in three spanish patients with infantile onset glycogen storage disease type II (pompe disease).","volume":"1","author":"Hirschhorn","year":"2002","journal-title":"Neuromuscul Disord"},{"key":"46","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/humu.20374","article-title":"Mutation profile of the GAA gene in 40 italian patients with late onset glycogen storage disease type II.","volume":"2","author":"Pittis","year":"2006","journal-title":"Hum Mutat"},{"key":"47","doi-asserted-by":"publisher","first-page":"278","DOI":"10.21037\/atm.2019.04.13","article-title":"Molecular genetics of pompe disease: a comprehensive overview.","volume":"7","author":"Dardis","year":"2019","journal-title":"Ann Transl Med"},{"key":"48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.gene.2015.02.023","article-title":"Novel GAA mutations in patients with pompe disease.","volume":"56","author":"Pesquero","year":"2015","journal-title":"Gene"},{"key":"49","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/humu.23854","article-title":"Extension of the pompe mutation database by linking disease-associated variants to clinical severity.","volume":"4","author":"Pijnappel","year":"2019","journal-title":"Hum Mutat"},{"key":"50","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.nmd.2015.07.002","article-title":"Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in pompe disease is associated with the classical adult phenotypical spectrum.","volume":"2","author":"Schoser","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"51","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/hmg\/3.7.1081","article-title":"A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII).","volume":"3","author":"Hirschhorn","year":"1994","journal-title":"Hum Mol Genet"},{"key":"52","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.nmd.2016.09.001","article-title":"The frequency of late-onset pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: a multicenter study.","volume":"2","author":"T\u00fcrkdo\u011fan","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"53","first-page":"85","article-title":"Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally \u201ccommon\u201d in white populations.","volume":"3","author":"Huie","year":"1999","journal-title":"J Med Genet"},{"key":"54","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s10038-007-0191-9","article-title":"Structural and biochemical studies on pompe disease and a \u201cpseudodeficiency of acid alpha-glucosidase\u201d.","volume":"5","author":"Sakuraba","year":"2007","journal-title":"J Hum Genet"},{"key":"55","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/genes11020135","article-title":"Novel mutations found in individuals with adult-onset pompe disease.","volume":"1","author":"Wilton","year":"2020","journal-title":"Genes (Basel)"},{"key":"56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset pompe disease.","volume":"6","author":"Halberthal","year":"2007","journal-title":"Neurology"},{"key":"57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymgmr.2017.10.009","article-title":"A molecular analysis of the GAA gene and clinical spectrum in 38 patients with pompe disease in Japan.","volume":"1","author":"Okuyama","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"58","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.18632\/aging.102879","article-title":"GAA compound heterozygous mutations associated with autophagic impairment cause cerebral infarction in pompe disease.","volume":"1","author":"Xia","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"59","doi-asserted-by":"publisher","first-page":"E27","DOI":"10.1002\/humu.20753","article-title":"Molecular and functional characterization of eight novel GAA mutations in italian infants with pompe disease.","volume":"2","author":"Di Rocco","year":"2008","journal-title":"Hum Mutat"},{"key":"60","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13023-014-0102-z","article-title":"Genotype-phenotype correlation in pompe disease, a step forward.","volume":"9","author":"Marrosu","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"61","first-page":"78","article-title":"Early is better? a new algorithm for early diagnosis in late onset pompe disease (LOPD).","volume":"3","author":"Musumeci","year":"2013","journal-title":"Acta Myol"},{"key":"62","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with pompe disease: a 10-year experience.","volume":"2","author":"Schoser","year":"2017","journal-title":"Eur J Neurol"},{"key":"63","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cccn.2004.04.009","article-title":"Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper.","volume":"34","author":"Casentini","year":"2004","journal-title":"Clin Chim Acta"},{"key":"64","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ymgme.2007.09.006","article-title":"Methods for a prompt and reliable laboratory diagnosis of pompe disease: report from an international consensus meeting.","volume":"9","author":"Ledvinov\u00e1","year":"2008","journal-title":"Mol Genet Metab"},{"key":"65","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/01.gim.0000217781.66786.9b","article-title":"Comparison of maltose and acarbose as inhibitors of Maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile pompe disease.","volume":"8","author":"Bali","year":"2006","journal-title":"Genet Med"},{"key":"66","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1373\/clinchem.2016.269027","article-title":"Mass spectrometry but not fluorimetry distinguishes affected and pseudodeficiency patients in newborn screening for pompe disease.","volume":"6","author":"Gelb","year":"2017","journal-title":"Clin Chem"},{"key":"67","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1093\/nar\/gnf056","article-title":"Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.","volume":"3","author":"Pals","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"68","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/mus.25042","article-title":"Next generation sequencing detection of late onset pompe disease.","volume":"5","author":"Nigro","year":"2016","journal-title":"Muscle Nerve"},{"key":"69","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1002\/ajmg.a.38333","article-title":"Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of pompe disease.","volume":"17","author":"Wong","year":"2017","journal-title":"Am J Med Genet A"},{"key":"70","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.nmd.2018.03.011","article-title":"Targeted gene panel screening is an effective tool to identify undiagnosed late onset pompe disease.","volume":"2","author":"Esposito","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"71","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.omtm.2019.12.016","article-title":"Novel GAA variants and mosaicism in pompe disease identified by extended analyses of patients with an incomplete DNA diagnosis.","volume":"1","author":"Hoefsloot","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"72","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1373\/clinchem.2011.178319","article-title":"Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in pompe disease and other glycogen storage diseases.","volume":"5","author":"Ruijter","year":"2012","journal-title":"Clin Chem"},{"key":"73","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1002\/jcp.26365","article-title":"Vacuolated PAS-positive lymphocytes as an hallmark of pompe disease and other myopathies related to impaired autophagy.","volume":"23","author":"Giordano","year":"2018","journal-title":"J Cell Physiol"},{"key":"74","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10545-009-9027-4","article-title":"PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for pompe disease.","volume":"3","author":"van der Ploeg","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"75","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/2013.jamaneurol.486","article-title":"Diagnosis of pompe disease: muscle biopsy vs blood-based assays.","volume":"7","author":"Straub","year":"2013","journal-title":"JAMA Neurol"},{"key":"76","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.nmd.2011.11.003","article-title":"Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset pompe disease lacking disease specific pathology.","volume":"2","author":"Nishino","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"77","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2051-5960-2-2","article-title":"The value of muscle biopsies in pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients.","volume":"2","author":"Raben","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"78","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.nmd.2019.09.011","article-title":"Clinical features of pompe disease with motor neuronopathy.","volume":"2","author":"Chien","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"79","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients.","volume":"1","author":"Schoser","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"80","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/mus.24620","article-title":"Electromyographic findings in 37 patients with adult-onset acid Maltase deficiency.","volume":"5","author":"Sorenson","year":"2015","journal-title":"Muscle Nerve"},{"key":"81","doi-asserted-by":"publisher","first-page":"e0190784","DOI":"10.1371\/journal.pone.0190784","article-title":"Quantification of intramuscular fat in patients with late-onset pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy.","volume":"1","author":"Staatz","year":"2018","journal-title":"PLoS One"},{"key":"82","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ana.24599","article-title":"Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort.","volume":"7","author":"Byrne","year":"2016","journal-title":"Ann Neurol"},{"key":"83","doi-asserted-by":"publisher","first-page":"e90377","DOI":"10.1371\/journal.pone.0090377","article-title":"Quantitative magnetic resonance imaging in limb-girdle muscular dystrophy 2I: a multinational cross-sectional study.","volume":"9","author":"Thornton","year":"2014","journal-title":"PLoS One"},{"key":"84","doi-asserted-by":"publisher","first-page":"10898","DOI":"10.1038\/s41598-018-29170-7","article-title":"Quantitative muscle MRI to follow up late onset pompe patients: a prospective study.","volume":"8","author":"D\u00edaz-Manera","year":"2018","journal-title":"Sci Rep"},{"key":"85","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymgme.2019.11.005","article-title":"Links between autophagy and disorders of glycogen metabolism - perspectives on pathogenesis and possible treatments.","volume":"12","author":"Koeberl","year":"2020","journal-title":"Mol Genet Metab"},{"key":"86","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the pathogenesis of disease.","volume":"13","author":"Kroemer","year":"2008","journal-title":"Cell"},{"key":"87","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.semcdb.2010.03.002","article-title":"Physiological role of autophagy as an intracellular recycling system: with an emphasis on nutrient metabolism.","volume":"2","author":"Mizushima","year":"2010","journal-title":"Semin Cell Dev Biol"},{"key":"88","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.cmet.2011.04.004","article-title":"Autophagy in the cellular energetic balance.","volume":"1","author":"Cuervo","year":"2011","journal-title":"Cell Metab"},{"key":"89","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fcell.2019.00114","article-title":"Transcriptional regulation of autophagy: mechanisms and diseases.","volume":"7","author":"Settembre","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"90","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fcell.2019.00179","article-title":"Biomedical implications of autophagy in macromolecule storage disorders.","volume":"7","author":"Sarkar","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"91","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.cca.2018.06.014","article-title":"Glycophagy: an emerging target in pathology.","volume":"48","author":"Chen","year":"2018","journal-title":"Clin Chim Acta"},{"key":"92","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/nan.12214","article-title":"Impaired autophagy affects acid \u03b1-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II.","volume":"4","author":"Sandri","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"93","doi-asserted-by":"publisher","first-page":"353","DOI":"10.15252\/emmm.201606547","article-title":"Modulation of mTOR signaling as a strategy for the treatment of pompe disease.","volume":"9","author":"Raben","year":"2017","journal-title":"EMBO Mol Med"},{"key":"94","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1017\/cjn.2016.37","article-title":"Pompe disease: diagnosis and management. Evidence-based guidelines from a canadian expert panel.","volume":"4","author":"Khan","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"95","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","article-title":"Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways.","volume":"14","author":"Ritchie","year":"2014","journal-title":"Pharmacol Ther"},{"key":"96","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","article-title":"Defects in calcium homeostasis and mitochondria can be reversed in pompe disease.","volume":"1","author":"Raben","year":"2015","journal-title":"Autophagy"},{"key":"97","doi-asserted-by":"publisher","first-page":"333","DOI":"10.22074\/cellj.2018.5238","article-title":"Mitochondrial variants in pompe disease: a comparison between classic and non-classic forms.","volume":"2","author":"Akrami","year":"2018","journal-title":"Cell J"},{"key":"98","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11523-018-0551-8","article-title":"Extracellular vesicles as miRNA nano-shuttles: dual role in tumor progression.","volume":"1","author":"Taverna","year":"2018","journal-title":"Target Oncol"},{"key":"99","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.bbrc.2010.11.026","article-title":"Niemann-pick type C fibroblasts have a distinct microRNA profile related to lipid metabolism and certain cellular components.","volume":"40","author":"Laaksonen","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"100","doi-asserted-by":"publisher","first-page":"15277","DOI":"10.1038\/s41598-019-51805-6","article-title":"Circulating microRNAs in fabry disease.","volume":"9","author":"Thum","year":"2019","journal-title":"Sci Rep"},{"key":"101","doi-asserted-by":"publisher","first-page":"4027606","DOI":"10.1155\/2019\/4027606","article-title":"Variables associated with a urinary MicroRNAs excretion profile indicative of renal fibrosis in fabry disease patients.","volume":"201","author":"Venera","year":"2019","journal-title":"Int J Chronic Dis"},{"key":"102","doi-asserted-by":"publisher","first-page":"27333","DOI":"10.18632\/oncotarget.25542","article-title":"A pilot study of circulating microRNAs as potential biomarkers of fabry disease.","volume":"9","author":"Duro","year":"2018","journal-title":"Oncotarget"},{"key":"103","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13023-019-1291-2","article-title":"The latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and pompe disease.","volume":"1","author":"Sparks","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"104","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1590\/1678-4685-GMB-2018-0092","article-title":"Sensitivity, advantages, limitations, and clinical utility of targeted next-generation sequencing panels for the diagnosis of selected lysosomal storage disorders.","volume":"4","author":"Giugliani","year":"2019","journal-title":"Genet Mol Biol"},{"key":"105","doi-asserted-by":"publisher","first-page":"287","DOI":"10.21037\/atm.2019.04.67","article-title":"Progress and challenges of gene therapy for pompe disease.","volume":"7","author":"Mingozzi","year":"2019","journal-title":"Ann Transl Med"},{"key":"106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.biochem.031209.093756","article-title":"From serendipity to therapy.","volume":"8","author":"Neufeld","year":"2011","journal-title":"Annu Rev Biochem"},{"key":"107","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13023-017-0693-2","article-title":"A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset pompe disease.","volume":"1","author":"Jayaram","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"108","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.omtm.2018.11.002","article-title":"AAV gene transfer with tandem promoter design prevents anti-transgene immunity and provides persistent efficacy in neonate pompe mice.","volume":"1","author":"Leborgne","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"109","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/mt.2008.133","article-title":"Correction of multiple striated muscles in murine pompe disease through adeno-associated virus-mediated gene therapy.","volume":"1","author":"Koeberl","year":"2008","journal-title":"Mol Ther"},{"key":"110","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-dose liver-targeted gene therapy for pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction.","volume":"4","author":"Koeberl","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"111","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy.","volume":"37","author":"L\u2019Italien","year":"2017","journal-title":"N Engl J Med"},{"key":"112","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1089\/hum.2013.233","article-title":"Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of crigler-najjar syndrome.","volume":"2","author":"Muro","year":"2014","journal-title":"Hum Gene Ther"},{"key":"113","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-biochem-060815-014607","article-title":"CRISPR\/Cas9 in genome editing and beyond.","volume":"8","author":"Qi","year":"2016","journal-title":"Annu Rev Biochem"},{"key":"114","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration.","volume":"54","author":"Li","year":"2016","journal-title":"Nature"},{"key":"115","doi-asserted-by":"publisher","first-page":"e0127048","DOI":"10.1371\/journal.pone.0127048","article-title":"nano-LC-MS\/MS for quantification of lyso-Gb3 and its analogues reveals a useful biomarker for fabry disease.","volume":"1","author":"Sakuraba","year":"2015","journal-title":"PLoS One"},{"key":"116","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in north east Italy.","volume":"4","author":"Burlina","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"117","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.3390\/ijms19123726","article-title":"Mutations in the GLA gene and LysoGb3: is it really anderson-fabry disease?","volume":"1","author":"Palladino","year":"2018","journal-title":"Int J Mol Sci"},{"key":"118","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1542\/peds.2016-0280C","article-title":"Newborn screening for pompe disease.","volume":"14","author":"Giugliani","year":"2017","journal-title":"Pediatrics"},{"key":"119","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1542\/peds.2016-0280B","article-title":"Introduction to the newborn screening, diagnosis, and treatment for pompe disease guidance supplement.","volume":"14","author":"Hwu","year":"2017","journal-title":"Pediatrics"},{"key":"120","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines.","volume":"7","author":"Bachurski","year":"2018","journal-title":"J Extracell Vesicles"},{"key":"121","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s10038-019-0603-7","article-title":"Newborn screening for pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients.","volume":"6","author":"Nakamura","year":"2019","journal-title":"J Hum Genet"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.103794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T09:24:52Z","timestamp":1602235492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.103794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":121,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,8,15]]}},"alternative-id":["103794","32745073"],"URL":"https:\/\/doi.org\/10.18632\/aging.103794","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]}}}